AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10525592 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15 mg/kg cisatracurium (3x ED(95))
Number of subjects: 45
Study 10525592 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg cisatracurium (2x ED(95))
Number of subjects: 45
Study 10525592 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg atracurium (2x ED(95))
Number of subjects: 45
Study 10525592 — intervention group
Group type: EXPERIMENTAL
Intervention: All three groups (0.1 mg/kg cisatracurium, 0.15 mg/kg cisatracurium, 0.5 mg/kg atracurium)
Number of subjects: 45
Study 7793585 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane
Number of subjects: 30
Study 7793585 — intervention group
Group type: EXPERIMENTAL
Intervention: Enflurane
Number of subjects: 30
Study 7793585 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 30
Study 1775892 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronized progesterone
Number of subjects: 44
Study 1775892 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 7018179 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN) 5 mg orally
Number of subjects: 12
Study 7018179 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol 1.0 mg i.v.
Number of subjects: 12
Study 7018179 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ISDN and pindolol
Number of subjects: 12
Study 7018179 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 6656169 — intervention group
Group type: EXPERIMENTAL
Intervention: 3100 NOON-Units (NU) with 3 injections in group A
Number of subjects: 28
Study 6656169 — intervention group
Group type: EXPERIMENTAL
Intervention: 9100 NOON-Units (NU) with 6 injections in group B
Number of subjects: 28
Study 6656169 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 28
Study 30370956 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin-topotecan (CT)
Number of subjects: 90
Study 30370956 — intervention group
Group type: EXPERIMENTAL
Intervention: Alvocidib, cytarabine, and mitoxantrone (FLAM)
Number of subjects: 90
Study 30370956 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus combined with mitoxantrone, etoposide, and cytarabine (S-MEC)
Number of subjects: 90
Study 30071980 — intervention group
Group type: EXPERIMENTAL
Intervention: New Forest Parenting Programme (n = 88)
Number of subjects: 164
Study 30071980 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (n = 76)
Number of subjects: 164
Study 27091540 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT)
Number of subjects: 24
Study 27091540 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 24474647 — intervention group
Group type: EXPERIMENTAL
Intervention: 9-beam lasercomb treatment in female subjects
Number of subjects: 269
Study 24474647 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-beam lasercomb treatment in female subjects
Number of subjects: 269
Study 24474647 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-beam lasercomb treatment in male subjects
Number of subjects: 269
Study 24474647 — intervention group
Group type: EXPERIMENTAL
Intervention: 9-beam lasercomb treatment in male subjects
Number of subjects: 269
Study 24474647 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-beam lasercomb treatment in male subjects
Number of subjects: 269
Study 24474647 — intervention group
Group type: COMPARATOR
Intervention: Sham device
Number of subjects: 269
Study 22761115 — intervention group
Group type: EXPERIMENTAL
Intervention: Sealed CO(2) insufflation
Number of subjects: 60
Study 22761115 — intervention group
Group type: COMPARATOR
Intervention: Open CO(2) insufflation
Number of subjects: 60
Study 22761115 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Sealed and Open CO(2) insufflation)
Number of subjects: 60
Study 20047816 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigue Severity Scale (FSS)
Number of subjects: 50
Study 20047816 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Self‐Maintenance Scale (PSMS)
Number of subjects: 50
Study 20047816 — intervention group
Group type: EXPERIMENTAL
Intervention: Handwriting performance (measured by ComPET)
Number of subjects: 50
Study 20047816 — intervention group
Group type: EXPERIMENTAL
Intervention: FSS, specific PSMS items, and handwriting measures
Number of subjects: 50
Study 17484373 — intervention group
Group type: COMPARATOR
Intervention: Lactulose 0 g (placebo)
Number of subjects: 24
Study 17484373 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactulose 2 g (low-dose)
Number of subjects: 24
Study 17484373 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactulose 4 g (high-dose)
Number of subjects: 24
Study 16286541 — intervention group
Group type: COMPARATOR
Intervention: 1 g/kg of IVIG on day 1 and placebo on day 2 (group 1)
Number of subjects: 173
Study 16286541 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g/kg of IVIG on 2 consecutive days (group 2)
Number of subjects: 173
Study 12515573 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropinirole
Number of subjects: 100
Study 12515573 — intervention group
Group type: COMPARATOR
Intervention: Levodopa plus benserazide
Number of subjects: 100
Study 10588559 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mL 1% lidocaine with epinephrine 1:200,000
Number of subjects: 20
Study 10588559 — intervention group
Group type: COMPARATOR
Intervention: 10 mL 1% lidocaine without epinephrine
Number of subjects: 20
Study 8961492 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine sublingually
Number of subjects: 52
Study 8961492 — intervention group
Group type: COMPARATOR
Intervention: Morphine via patient-controlled analgesia system
Number of subjects: 52
Study 1762067 — intervention group
Group type: EXPERIMENTAL
Intervention: R-ibuprofen (600 mg) plus S-[aromatic-2H4]ibuprofen (10 mg)
Number of subjects: 8
Study 1762067 — intervention group
Group type: EXPERIMENTAL
Intervention: S-ibuprofen (600 mg)
Number of subjects: 8
Study 1762067 — intervention group
Group type: EXPERIMENTAL
Intervention: Racemic ibuprofen (800 mg) plus S-[aromatic-2H4]ibuprofen (10 mg)
Number of subjects: 8
Study 1762067 — intervention group
Group type: EXPERIMENTAL
Intervention: Racemic ibuprofen
Number of subjects: 8
Study 1762067 — intervention group
Group type: EXPERIMENTAL
Intervention: S-ibuprofen
Number of subjects: 8
Study 1762067 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboxyibuprofen
Number of subjects: 8
Study 7044098 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin 120 mg/m2
Number of subjects: 37
Study 7044098 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin 60 mg/m2
Number of subjects: 37
Study 7044098 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin 60 mg/m2 to 120 mg/m2 crossover
Number of subjects: 37
Study 7044098 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin 60 mg/m2 and 120 mg/m2
Number of subjects: 37
Study 31589177 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 10
Study 31589177 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D status
Number of subjects: 10
Study 31589177 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic polymorphisms
Number of subjects: 10
Study 31589177 — intervention group
Group type: EXPERIMENTAL
Intervention: Gut microbiome influence
Number of subjects: 10
Study 29017158 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 polyunsaturated fatty acids (PUFAs) 2,700 mg/day
Number of subjects: 44
Study 29017158 — intervention group
Group type: COMPARATOR
Intervention: Placebo (900 mg of edible paraffin)
Number of subjects: 44
Study 26445224 — intervention group
Group type: EXPERIMENTAL
Intervention: Booklet only
Number of subjects: 186
Study 26445224 — intervention group
Group type: EXPERIMENTAL
Intervention: Booklet plus nurse support (up to four 30-minute sessions)
Number of subjects: 186
Study 23414234 — intervention group
Group type: EXPERIMENTAL
Intervention: Assertive Outreach (AO)
Number of subjects: 0
Study 23414234 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 0
Study 22072466 — intervention group
Group type: COMPARATOR
Intervention: Conventional injection technique (CI)
Number of subjects: 40
Study 22072466 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal phalanx injection technique (P1I)
Number of subjects: 40
Study 19336509 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol (D3) - 50,000 IU weekly
Number of subjects: 30
Study 19336509 — intervention group
Group type: EXPERIMENTAL
Intervention: Ergocalciferol (D2) - 50,000 IU weekly
Number of subjects: 30
Study 19336509 — intervention group
Group type: COMPARATOR
Intervention: UV light therapy - exposed skin to UV light five times a week
Number of subjects: 30
Study 17719312 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril (2 to 4 mg)
Number of subjects: 57
Study 17719312 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 15013936 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 4937
Study 15013936 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4937
Study 15299053 — intervention group
Group type: EXPERIMENTAL
Intervention: (123)I‐MIBG myocardial scintigraphy
Number of subjects: 9
Study 15299053 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (n=11; 11 men; mean age 37.6 ± 9.3 years)
Number of subjects: 9
Study 10361264 — intervention group
Group type: EXPERIMENTAL
Intervention: Griseofulvin plus oral prednisolone
Number of subjects: 30
Study 10361264 — intervention group
Group type: COMPARATOR
Intervention: Griseofulvin alone
Number of subjects: 30
Study 8528724 — intervention group
Group type: EXPERIMENTAL
Intervention: Health risk appraisal (HRA) activity
Number of subjects: 0
Study 8528724 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 1773708 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixtard
Number of subjects: 7
Study 1773708 — intervention group
Group type: EXPERIMENTAL
Intervention: Actraphane
Number of subjects: 7
Study 1773708 — intervention group
Group type: EXPERIMENTAL
Intervention: Humulin M3
Number of subjects: 7
Study 1773708 — intervention group
Group type: COMPARATOR
Intervention: NPH insulin alone
Number of subjects: 7
Study 1773708 — intervention group
Group type: EXPERIMENTAL
Intervention: Syringe mixed regular and NPH insulin
Number of subjects: 7
Study 7333003 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled metaproterenol given 10 min before exercise
Number of subjects: 24
Study 7333003 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled metaproterenol given 1 hr before exercise
Number of subjects: 24
Study 7333003 — intervention group
Group type: EXPERIMENTAL
Intervention: Metaproterenol tablets given 1 hr before exercise
Number of subjects: 24
Study 7333003 — intervention group
Group type: EXPERIMENTAL
Intervention: Metaproterenol tablets given 2 hr before exercise
Number of subjects: 24
Study 7333003 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 31413896 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum neurotoxin type A treatment
Number of subjects: 50
Study 30006297 — intervention group
Group type: EXPERIMENTAL
Intervention: High Vitamin D
Number of subjects: 732
Study 30006297 — intervention group
Group type: EXPERIMENTAL
Intervention: Low n-3PUFA
Number of subjects: 732
Study 30006297 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D deficiency ([25(OH)D] < 20 ng/ml)
Number of subjects: 732
Study 27858079 — intervention group
Group type: EXPERIMENTAL
Intervention: bFGF 35000IU + normal saline 20 mL, compression inhalation, day 1, every 20min, continued for 3 d
Number of subjects: 40
Study 27858079 — intervention group
Group type: COMPARATOR
Intervention: normal saline 5 mL + dexamethasone 5 mg + gentamicin 80000 U + chymotrypsin 4000 U, compression inhalation, twice a day, every 20 min, continued for 3 d
Number of subjects: 40
Study 25070547 — intervention group
Group type: COMPARATOR
Intervention: Continuous cycling (CC) using 20 mcg ethinyl estradiol/100 mcg levonorgestrel with no hormone-free interval
Number of subjects: 31
Study 25070547 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased dose (ID) using 30 mcg ethinyl estradiol/150 mcg levonorgestrel cyclically
Number of subjects: 31
Study 22883337 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 127
Study 22883337 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127
Study 20564362 — intervention group
Group type: EXPERIMENTAL
Intervention: Reconciliation workshop with PTSD psychoeducation
Number of subjects: 0
Study 20564362 — intervention group
Group type: EXPERIMENTAL
Intervention: Reconciliation workshop without PTSD psychoeducation
Number of subjects: 0
Study 20564362 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 0
Study 18490196 — intervention group
Group type: EXPERIMENTAL
Intervention: CSE 900 mg
Number of subjects: 0
Study 18490196 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15666173 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk thistle (450 mg extract capsules t.i.d. from day 2 to day 30)
Number of subjects: 16
Study 15666173 — intervention group
Group type: COMPARATOR
Intervention: Control (no plant extract)
Number of subjects: 16
Study 15666173 — intervention group
Group type: EXPERIMENTAL
Intervention: Meta-analysis of milk thistle-indinavir trials
Number of subjects: 16
Study 12618646 — intervention group
Group type: EXPERIMENTAL
Intervention: Test Request Form (TRF)
Number of subjects: 1412
Study 12618646 — intervention group
Group type: EXPERIMENTAL
Intervention: Memorandum Pocket Card (MPC)
Number of subjects: 1412
Study 12618646 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual intervention group (TRF + MPC)
Number of subjects: 1412
Study 12618646 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1412
Study 10204754 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefopam (20 mg)
Number of subjects: 10
Study 10204754 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 8805965 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal biofeedback (TBF) training for hand (7 sessions) and foot (9 sessions) warming
Number of subjects: 42
Study 8805965 — intervention group
Group type: COMPARATOR
Intervention: Monitoring BPs at home (control group)
Number of subjects: 42
Study 8805965 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal biofeedback (TBF) training
Number of subjects: 42
Study 8805965 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive follow-up emphasizing regular home practice with an electronic TBF device
Number of subjects: 42
Study 8805965 — intervention group
Group type: COMPARATOR
Intervention: Regular follow-up (visits every 3 months)
Number of subjects: 42
Study 1625204 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine (0, 12.5, 25 and 50 mg, i.v.)
Number of subjects: 8
Study 1625204 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine (0, 1.2 and 2.5 mg given orally 2 hr before the cocaine injection)
Number of subjects: 8
Study 1625204 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine + Bromocriptine
Number of subjects: 8
Study 1625204 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine alone
Number of subjects: 8
Study 6435446 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim/sulfamethoxazole
Number of subjects: 43
Study 6435446 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 43
Study 30421335 — intervention group
Group type: EXPERIMENTAL
Intervention: On-meals (home delivery of 10 meals/week for 12 weeks)
Number of subjects: 44
Study 30421335 — intervention group
Group type: COMPARATOR
Intervention: Off-meals (12 weeks usual care and a Choose MyPlate healthy eating brochure)
Number of subjects: 44
Study 30421335 — intervention group
Group type: EXPERIMENTAL
Intervention: On-meals
Number of subjects: 44
Study 28334273 — intervention group
Group type: EXPERIMENTAL
Intervention: Mendelian randomization-based pathway enrichment analysis (MRPEA)
Number of subjects: 0
Study 28334273 — intervention group
Group type: COMPARATOR
Intervention: Traditional pathway association analysis (TPAA)
Number of subjects: 0
Study 26940371 — intervention group
Group type: EXPERIMENTAL
Intervention: (+)‐delmopinol
Number of subjects: 0
Study 26940371 — intervention group
Group type: EXPERIMENTAL
Intervention: (‐)‐delmopinol
Number of subjects: 0
Study 26940371 — intervention group
Group type: COMPARATOR
Intervention: (±)‐delmopinol (racemate)
Number of subjects: 0
Study 26940371 — intervention group
Group type: EXPERIMENTAL
Intervention: All three test solutions
Number of subjects: 0
Study 26940371 — intervention group
Group type: EXPERIMENTAL
Intervention: (+)‐delmopinol and (‐)‐delmopinol
Number of subjects: 0
Study 24335542 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical thrombectomy with Solitaire stent
Number of subjects: 25
Study 22609981 — intervention group
Group type: COMPARATOR
Intervention: Wallflex stent (n = 28)
Number of subjects: 123
Study 22609981 — intervention group
Group type: EXPERIMENTAL
Intervention: D-type stent (n = 30)
Number of subjects: 123
Study 22609981 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative bridging stents (combined Wallflex and D-type)
Number of subjects: 123
Study 20620265 — intervention group
Group type: EXPERIMENTAL
Intervention: Monotherapy or combination therapy for manic/mixed episodes
Number of subjects: 795
Study 20620265 — intervention group
Group type: EXPERIMENTAL
Intervention: Atypical antipsychotics (monotherapy or in combination)
Number of subjects: 795
Study 17936411 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab (40 mg) every other week for the first 15 weeks
Number of subjects: 1212
Study 17936411 — intervention group
Group type: COMPARATOR
Intervention: Placebo every other week for the first 15 weeks
Number of subjects: 1212
Study 17936411 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab (continuous treatment)
Number of subjects: 1212
Study 17936411 — intervention group
Group type: COMPARATOR
Intervention: Placebo (rerandomized from adalimumab)
Number of subjects: 1212
Study 15748108 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive maxillary plates (IO+)
Number of subjects: 0
Study 15748108 — intervention group
Group type: COMPARATOR
Intervention: No passive maxillary plates (IO-)
Number of subjects: 0
Study 15748108 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (IO+ and IO-)
Number of subjects: 0
Study 12418119 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 W UHF electromagnetic fields combined with bicycle exercise
Number of subjects: 112
Study 12418119 — intervention group
Group type: COMPARATOR
Intervention: Bicycle exercise alone
Number of subjects: 112
Study 12418119 — intervention group
Group type: COMPARATOR
Intervention: Placebo procedures with therapeutic exercises
Number of subjects: 112
Study 10334750 — intervention group
Group type: EXPERIMENTAL
Intervention: Sending patients a copy of their referral letter
Number of subjects: 2078
Study 10334750 — intervention group
Group type: COMPARATOR
Intervention: Control group (no copy letter)
Number of subjects: 2078
Study 9005787 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin (200 mg intravenously twice a day for 3 days, then orally at the same dosage)
Number of subjects: 15
Study 9005787 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin
Number of subjects: 15
Study 11885246 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothpaste containing amyloglucosidase and glucose oxidase (Z)
Number of subjects: 20
Study 11885246 — intervention group
Group type: COMPARATOR
Intervention: Placebo toothpaste (P)
Number of subjects: 20
Study 3087678 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin (22.5 cm2 mean dose)
Number of subjects: 11
Study 3087678 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 30953306 — intervention group
Group type: EXPERIMENTAL
Intervention: Opt-out testing
Number of subjects: 0
Study 30953306 — intervention group
Group type: EXPERIMENTAL
Intervention: $1 financial incentive
Number of subjects: 0
Study 30953306 — intervention group
Group type: EXPERIMENTAL
Intervention: $5 financial incentive
Number of subjects: 0
Study 30953306 — intervention group
Group type: EXPERIMENTAL
Intervention: $10 financial incentive
Number of subjects: 0
Study 30953306 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of opt-out testing and financial incentives
Number of subjects: 0
Study 30953306 — intervention group
Group type: COMPARATOR
Intervention: Opt-in testing
Number of subjects: 0
Study 30953306 — intervention group
Group type: COMPARATOR
Intervention: No incentive
Number of subjects: 0
Study 30286774 — intervention group
Group type: EXPERIMENTAL
Intervention: ACLR by the transtibial (TT) method
Number of subjects: 7
Study 30286774 — intervention group
Group type: EXPERIMENTAL
Intervention: ACLR by the anteromedial (AM) portal method
Number of subjects: 7
Study 30286774 — intervention group
Group type: COMPARATOR
Intervention: Intact ACL
Number of subjects: 7
Study 27502776 — intervention group
Group type: EXPERIMENTAL
Intervention: Demand-creation intervention (small group, couple and male-focused interactive sessions, reinforced with testimonies from 'expert couples', and invitation coupons to test together)
Number of subjects: 1174
Study 27502776 — intervention group
Group type: COMPARATOR
Intervention: Control group (general adult health education sessions without invitation coupons)
Number of subjects: 1174
Study 27502776 — intervention group
Group type: EXPERIMENTAL
Intervention: Demand-creation intervention
Number of subjects: 1174
Study 27502776 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1174
Study 25234925 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooled dialysate (0.5°C below core body temperature)
Number of subjects: 73
Study 25234925 — intervention group
Group type: COMPARATOR
Intervention: Standard dialysate (37°C)
Number of subjects: 73
Study 22775591 — intervention group
Group type: EXPERIMENTAL
Intervention: Training and tailored outreach support
Number of subjects: 4
Study 22127938 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinforced feedback in virtual environment (RFVE) therapy
Number of subjects: 80
Study 22127938 — intervention group
Group type: COMPARATOR
Intervention: Traditional neuromotor rehabilitation (TNR)
Number of subjects: 80
Study 22127938 — intervention group
Group type: EXPERIMENTAL
Intervention: RFVE therapy in haemorrhagic group
Number of subjects: 80
Study 22127938 — intervention group
Group type: COMPARATOR
Intervention: TNR therapy in haemorrhagic group
Number of subjects: 80